Financial Performance - The company's operating revenue for 2024 was ¥1,195,718,179.72, a decrease of 41.10% compared to ¥2,030,233,466.71 in 2023[6]. - The net profit attributable to shareholders for 2024 was -¥650,130,617.85, representing a decline of 43.82% from -¥452,046,680.05 in 2023[6]. - The basic earnings per share for 2024 was -¥1.50, down 42.86% from -¥1.05 in 2023[6]. - The total assets at the end of 2024 were ¥2,626,041,333.84, a reduction of 31.63% from ¥3,841,158,437.01 at the end of 2023[6]. - The company's cash flow from operating activities for 2024 was -¥47,018,889.30, an improvement of 8.87% compared to -¥51,594,597.21 in 2023[6]. - The company's net assets attributable to shareholders at the end of 2024 were -¥411,810,939.89, a decrease of 219.27% from ¥345,287,512.91 at the end of 2023[6]. - The company's total revenue for 2024 was ¥1,195,718,179.72, representing a year-on-year decrease of 41.10% from ¥2,030,233,466.7 in 2023[42]. - The construction materials and chemicals segment generated ¥544,051,627.22, accounting for 45.50% of total revenue, down 47.53% from ¥1,036,797,546.46 in 2023[45]. - The pharmaceutical segment contributed ¥625,260,185.91, which is 52.29% of total revenue, reflecting a decrease of 35.31% from ¥966,477,588.69 in 2023[45]. - Domestic revenue was ¥953,817,087.21, making up 79.77% of total revenue, a decline of 45.36% from ¥1,745,760,779.90 in 2023[45]. Internal Control and Audit - The company reported a significant internal control deficiency in areas such as related party transactions, fund management, and information disclosure, which has affected the reliability of its financial reporting[4]. - The company's financial report has received a qualified audit opinion from Tianjian Accounting Firm, indicating potential issues in financial accuracy[4]. - The company's financial reporting and internal control deficiencies have been detailed in the 2024 Internal Control Self-Assessment Report[4]. - The internal control system has been improved to adapt to changing external environments and internal management requirements[112]. - San Sheng Co. failed to maintain effective internal control over financial reporting as of December 31, 2024, according to the internal control audit report[116]. - The internal control audit report issued by the accounting firm contains a negative opinion due to significant internal control deficiencies related to related party transactions and fund management[117]. - The company reported two significant defects in financial reporting internal controls during the evaluation period[115]. Business Strategy and Development - The company has expanded its business into the pharmaceutical manufacturing sector, acquiring 100% of Baikang Pharmaceutical in June 2016 and 60% of Chunrui Chemical in June 2017[19]. - The pharmaceutical manufacturing industry is a key focus for the company, aligning with national policies aimed at enhancing healthcare and economic development[32]. - The company has completed a full industry chain layout in pharmaceutical research and development, intermediates, active pharmaceutical ingredients, and formulations through diversification strategies and acquisitions[33]. - The company operates primarily in the construction materials sector, heavily influenced by macroeconomic conditions and infrastructure investments[30]. - The company's diversified strategy has effectively reduced operational risks associated with macroeconomic cycles, enhancing overall business stability[36]. - The company has established a dual-driven business model of "construction materials and chemicals + pharmaceutical manufacturing," effectively reducing the impact of raw material price fluctuations[41]. - The company aims to strengthen its innovation capabilities and improve economic efficiency and core competitiveness through ongoing research and development efforts[44]. Environmental Compliance - San Sheng Co. strictly complied with multiple environmental protection laws and standards in 2024, including the Air Pollution Prevention and Control Law and the Water Pollution Prevention and Control Law[120]. - The company reported a total emission of 2.689 tons of particulate matter, which is within the regulatory limits set by the relevant standards[121]. - The company achieved a total phosphorus discharge of 2.22 t/a, adhering to the standard of ≤40 mg/L[123]. - The company has set a target to reduce total nitrogen emissions to 1.36 t/a in the upcoming year[123]. - The company plans to enhance its wastewater treatment capacity to further lower COD levels to 21.0 t/a[123]. - The company is focusing on improving its air quality management by reducing VOCs emissions by 10% in the next fiscal year[123]. - The company has implemented automatic online monitoring systems for waste gas and wastewater treatment facilities to ensure compliance with national and industry standards[127]. Governance and Management - The company has maintained a stable leadership team with no resignations or dismissals reported during the current term[89]. - The current board includes professionals with backgrounds in engineering, finance, and management, enhancing the company's strategic capabilities[90][92][93]. - The independent directors bring diverse expertise, contributing to robust governance and strategic oversight[90][91]. - The company is committed to maintaining transparency and accountability in its operations, as evidenced by the structured reporting of management changes[88]. - The total pre-tax remuneration for directors, supervisors, and senior management in the reporting period amounted to CNY 597.46 million[99]. - The remuneration for the chairman, Yan Huan, was CNY 48.28 million, while the total remuneration for the general manager, Zhang Zhiqiang, was CNY 115.88 million[98]. - The company has established a performance-oriented compensation system, including base salary, performance bonuses, and incentives to motivate employees[107]. Legal and Financial Issues - The company is facing significant financial pressure and has applied for bankruptcy reorganization[79]. - The company is involved in a legal dispute regarding a loan of 100 million, with a total repayment obligation of 61.485 million, including principal and interest[153]. - The company has been under administrative supervision multiple times since 2020 due to non-operating fund occupation and irregular guarantees[139]. - The company has incurred a financial cost of RMB 38.78 million due to the occupation of funds calculated until November 5, 2024[139]. - The company is currently in discussions regarding the repayment strategy for the outstanding loan[138]. - The company has recognized a provision for expected liabilities amounting to RMB 1,524.04 million related to SSC Construction PLC's debts[139]. - The company has been involved in multiple legal disputes regarding loans and guarantees, impacting its financial position and liquidity[195].

证券代码：002742 证券简称：ST三圣 公告编号：2025-25号 重庆三圣实业股份有限公司 关于控股股东股份新增轮候冻结的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别风险提示： 控股股东累计被冻结股份数量（含本次）占其所持公司股份数量比例超过 80%，请投资者注意相关风险。 重庆三圣实业股份有限公司（以下简称"公司"）于近日通过中国证券登记 结算有限责任公司系统查询，获悉控股股东潘先文先生所持公司股份存在新增轮 候冻结情形,现将具体情况公告如下： 二、股东股份累计冻结情况 | 股东名称 | 持股数量 | 持股比例 | 累计被司法冻结 | 占其所持股份比 | 占公司总股本 | | --- | --- | --- | --- | --- | --- | | | | （%） | 数量 | 例（%） | 比例（%） | | 潘先文 | 104,554,232 | 24.21 | 104,554,232 | 100 | 24.21 | （二）截至本公告披露日，上述股东所持股份累计被轮候冻结的情况如 下： 股东名 称 是否为第 一大股东 及一致行 动人 ...

一、协议履行进展 近日，为顺利推进三圣股份重整程序，公司与深圳高新投集团在平等、自愿、 协商一致的基础上，针对《执行和解协议》解除条款做出部分变更并达成如下补 充协议（以下简称 "本补充协议"），以兹共同遵守： 证券代码：002742 证券简称：ST 三圣 公告编号：2025-24 号 重庆三圣实业股份有限公司 关于签署《执行和解协议之补充协议》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆三圣实业有限公司（以下简称"公司"或"三圣股份"）于 2024 年 12 月 18 日与深圳市高新投集团有限公司（以下简称"深圳高新投集团"签署《执 行和解协议》，详见公司于 2024 年 12 月 19 日在巨潮资讯网上披露的《关于签 署<执行和解协议>的公告》（公告编号：2024-94 号）。 3、本补充协议是《执行和解协议》的补充协议，与《执行和解协议》具有 同等效力，系《执行和解协议》不可分割的一部分。本补充协议与《执行和解协 议》不一致之处，以本补充协议为准；本补充协议未约定的事项，以《执行和解 协议》约定为准。 二、本次协议对公司的影响 《执行和解 ...

证券代码：002742 证券简称：ST 三圣 公告编号：2025-22 号 针对公司股票交易异常波动，现将相关情况说明如下： 1、公司、控股股东和实际控制人不存在关于公司的应披露而未披露的重大 事项，或处于筹划阶段的重大事项。 2、公司前期所披露的信息，不存在需要更正、补充之处。 3、公司未发现近期公共媒体报道了可能或已经对公司股票交易价格产生较 大影响的未公开重大信息。 4、公司已披露的经营情况、内外部经营环境未发生重大变化。 5、公司控股股东、实际控制人在股票交易波动期间不存在买卖公司股票的 情形。 重庆三圣实业股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 重庆三圣实业股份有限公司（以下简称"公司"）股票（证券简称：ST 三 圣，证券代码：002742）日收盘价格涨跌幅偏离值累计异常，2025 年 4 月 11 日、 2025 年 4 月 14 日、2025 年 4 月 15 日，连续 3 个交易日收盘价涨幅偏离值累计 达到 13.82%。根据《深圳证券交易所交易规则》的有关规定，属于股 ...

证券代码：002742 证券简称：ST 三圣 公告编号：2025-23 号 重庆三圣实业股份有限公司 关于公司股票交易可能被实施 退市风险警示的提示性公告 根据公司于 2025 年 1 月 21 日在巨潮资讯网（www.cninfo.com.cn）披露的 《2024 年年度业绩预告的补充公告》，预计 2024 年度公司期末净资产为-39,000 万元至-26,000 万元。根据《深圳证券交易所股票上市规则》9.3.1 第一款第（二） 项的规定，上市公司出现"最近一个会计年度经审计的期末净资产为负值"的情 形，公司股票交易将在 2024 年年度报告披露后被实施退市风险警示（在股票简 称前冠以*ST 字样）。 根据《深圳证券交易所股票上市规则》9.3.3 的规定："上市公司预计将出 现本规则第 9.3.1 条第一款第一项至第三项情形的，应当在相应的会计年度结束 后一个月内，披露公司股票交易可能被实施退市风险警示的风险提示公告，并在 披露年度报告前至少再披露两次风险提示公告。" 二、其他说明 1、截至本公告披露日，公司 2024 年度审计工作仍在推进当中，具体财务数 据以公司正式披露的经审计的 2024 年年度报告 ...

ST三圣（002742）公告，公司预计2024年度期末净资产为-3.9亿元至-2.6亿元。根据《深圳证券交易所 股票上市规则》相关规定，公司股票交易将在2024年年度报告披露后被实施退市风险警示。 ...

ST三圣（002742）发布异动公告，公司、控股股东和实际控制人不存在应披露而未披露的重大事项， 或处于筹划阶段的重大事项。公司前期所披露的信息，不存在需要更正、补充之处。公司未发现近期公 共媒体报道了可能或已经对公司股票交易价格产生较大影响的未公开重大信息。公司已披露的经营情 况、内外部经营环境未发生重大变化。 ...

2024年10月30日公司发布的三季报数据显示，前三季度公司共实现营业总收入9.86亿元，同比下降 38.96%，实现净利润-0.40亿元，同比增长69.59%。1月21日公司公布了2024年业绩预告，预计实现净利 润-6.60亿元至-4.60亿元。（数据宝） 近日该股表现 | 日期 | 当日涨跌幅（%） | 换手率（%） | 主力资金净流入（万元） | | --- | --- | --- | --- | | 2025.04.14 | 4.93 | 1.96 | -629.54 | | 2025.04.11 | 4.91 | 2.85 | 692.98 | | 2025.04.10 | 3.75 | 1.85 | 221.73 | | 2025.04.09 | 1.36 | 1.89 | -138.58 | | 2025.04.08 | 3.95 | 2.74 | 230.45 | | 2025.04.07 | -5.09 | 1.13 | -75.71 | | 2025.04.03 | 0.27 | 0.96 | -267.35 | | 2025.04.02 | -2.62 | 1.31 | -302.93 ...

证券代码：002742 证券简称：ST 三圣 公告编号：2025-21 号 重庆三圣实业股份有限公司 关于公司申请重整及法院接收申请材料的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、重庆三圣实业股份有限公司（以下简称"公司"）于 2025 年 4 月 7 日 正式向重庆市第五中级人民法院（以下简称"重庆五中院"）递交了重整申请 材料，重庆五中院审查后接收公司重整申请材料（案号：（2025）渝 05 破申 224 号）。公司重整申请材料被重庆五中院接收后，公司将继续依法依规推进 重整相关工作。 二、风险提示 1、公司递交的重整申请是否被法院裁定受理，尚存在不确定性。敬请广大 投资者注意投资风险。 2、如法院裁定受理公司的重整申请，公司将依法配合法院及管理人开展重 整相关工作，依法履行债务人的法定义务。根据《深圳证券交易所股票上市规 则》（以下简称《深交所股票上市规则》）第 9.4.1 条的相关规定，如法院依法 裁定受理公司重整，公司股票将在重整申请受理后被实施退市风险警示 （*ST），请投资者注意风险。 3、如法院裁定受理公司的重整申请 ...

具体内容详见公司于 2024 年 6 月 7 日披露于《上海证券报》、《证券时报》、 和巨潮资讯网（www.cninfo.com.cn）的《2023 年年度股东大会决议公告》。 证券代码：002742 证券简称：ST 三圣 公告编号：2025-20 号 重庆三圣实业股份有限公司 关于公司为全资子公司提供担保的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 公司及控股子公司的对外担保总额超过公司 2023 年度经审计净资产 100%， 请投资者充分关注担保风险。 一、担保情况概述 重庆三圣实业股份有限公司（以下简称"公司"）于 2023 年年度股东大会 审议通过了《关于公司及子公司 2024 年度担保计划的议案》，同意公司在额度 内为全资子公司辽源市百康药业有限责任公司（以下简称"百康药业"）提供担 保。 近日，百康药业与吉林银行股份有限公司辽源金汇支行签订《借款展期合同》， 展期借款金额 5,000 万元。公司将继续提供担保，担保金额为本金人民币 5,000 万元及相关利息等费用。 二、被担保人基本情况 成立日期：1995 年 2 月 24 ...